International Researchers Poised to Learn New Insights About C2N Diagnostics’ Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference

ST. LOUIS--(BUSINESS WIRE)-- C2N Diagnostics, a leader in advanced brain health diagnostics, will offer multiple presentations and posters to highlight new, important insights relating to its PrecivityAD® blood test, p-tau MAA™ and other unique biomarkers that aid healthcare providers in diagnosing Alzheimer’s disease at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

Of high interest will be multiple late-breaker oral presentations regarding C2N innovations, including CEO Dr. Joel B. Braunstein’s on December 2. During the presentation he will share new data about the clinical diagnostic usefulness of the PrecivityAD® test and its impact on medical decision-making among practicing neurologists.

Other C2N-related presentations at CTAD, occurring November 29 – December 2 in San Francisco, include the following:

Tuesday, November 29 (all times PST)

10:15 a.m.
CTAD EU/US Task Force on Blood Biomarkers
Point of view from assay industry
Dr. Joel B. Braunstein, C2N Diagnostics, St. Louis, MO (United States)

Wednesday, November 30

9:20 a.m.
CTAD 2022 fluid biomarker symposium: Recent advances in plasma and CSF Alzheimer biomarkers to improve clinical practice and trials

Oral Presentations
1: Relationship between blood plasma and CSF measures of Aβ 42/40, tau, and NfL species for tracking drug effects in clinical trials of Alzheimer’s disease
Randall J. Bateman, Washington University School of Medicine, St. Louis, MO (United States)
3: Implementation of plasma biomarkers into clinical practice and trials
Oskar Hansson, Lund University, Lund (Sweden)

10:30 a.m.
Late Breaker #1 – Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials
Keith Johnson, Massachusetts General Hospital, Boston, MA (United States)

10:45 a.m.
Late Breaker #2 – Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD
Robert Rissman, UC San Diego, La Jolla, CA (United States)

3:15 p.m.
Late Breaker #4 – CSF MTBR-tau243 is a non-amyloid specific biomarker of neurofibrillary tangles of Alzheimer’s disease.
Kanta Horie, Washington University School of Medicine, St. Louis, MO (United States)

Friday, December 2

9:20 a.m.
Late Breaker #12 – Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients with Symptoms of Cognitive Impairment
Dr. Joel B. Braunstein, C2N Diagnostics, St. Louis, MO (United States)

CTAD Posters Featuring Data on the PrecivityAD® Test

Theme – Clinical Trials: Methodology
Tuesday, November 29 at 4:00 p.m. to Wednesday, November 30 at 6:00 p.m.

LP09 The AlzMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials
Sarah Walter, Alzheimer’s Therapeutic Research Institute, USC – San Diego, CA (United States)

Theme – Clinical Trials: Biomarkers including plasma

Thursday, December 1 at 8:00 a.m.- 6:00 p.m.
P109 Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s Disease
Charisse N. Winston, UC San Diego, La Jolla, CA (United States)

P118 Recruitment of amyloid positive individuals and early Alzheimer’s patients in a primary care setting – results from the BioFINDER Primary Care study
Sebastian Palmqvist, Lund University, Malmö (Sweden)

P121 Use of the PrecivityAD® blood test in regular clinical practice: Preliminary observations from a dementia clinic
Jonathan Drake, Rhode Island Hospital, Providence, RI (United States)

About C2N Diagnostics, LLC

CN Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. CN strives to provide exceptional laboratory services and products in the field of brain health. CN’s biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. For more information visit

View source version on


Adam Shapiro

Source: C2N Diagnostics

Back to news